Free tool
FAERS Monitor: Nuvaring
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021187 or its brand name (Nuvaring, Ethinyl Estradiol, Etonogestrel). Reports on generic versions are filed under their own applications.
Reports
21,475
Serious
10,461
49% of reports
Hospitalization
6,033
Death reported
280
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pulmonary embolism3,951
- deep vein thrombosis2,659
- inappropriate schedule of drug administration2,229
- device expulsion1,366
- no adverse event1,204
- headache1,151
- metrorrhagia1,132
- incorrect drug administration duration1,017
- nausea1,012
- unintended pregnancy956
- depression910
- anxiety862
- migraine801
- off label use726
- menorrhagia625
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,304 |
| 2005 | 130 |
| 2006 | 255 |
| 2007 | 173 |
| 2008 | 190 |
| 2009 | 483 |
| 2010 | 678 |
| 2011 | 1,020 |
| 2012 | 1,697 |
| 2013 | 2,982 |
| 2014 | 3,782 |
| 2015 | 1,561 |
| 2016 | 1,659 |
| 2017 | 1,512 |
| 2018 | 1,184 |
| 2019 | 747 |
| 2020 | 690 |
| 2021 | 347 |
| 2022 | 315 |
| 2023 | 186 |
| 2024 | 184 |
| 2025 | 164 |
| 2026 | 232 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| unintended pregnancySignal | 956 | 98.5 | 92.3 | 83,799 |
| metrorrhagiaSignal | 1,132 | 69.6 | 65.6 | 71,418 |
| pulmonary embolismSignal | 3,951 | 42.4 | 41.2 | 153,888 |
| deep vein thrombosisSignal | 2,659 | 41.7 | 40.2 | 101,693 |
| incorrect drug administration durationSignal | 1,017 | 36.7 | 34.5 | 34,055 |
| menorrhagiaSignal | 625 | 32.2 | 29.7 | 18,258 |
| inappropriate schedule of drug administrationSignal | 2,229 | 31.6 | 30.4 | 64,271 |
| device expulsionSignal | 1,366 | 21.1 | 20.0 | 25,600 |
| migraineSignal | 801 | 8.3 | 7.7 | 5,099 |
| no adverse eventSignal | 1,204 | 6.5 | 6.2 | 5,662 |
| depressionSignal | 910 | 3.9 | 3.7 | 1,998 |
| anxietySignal | 862 | 3.0 | 2.8 | 1,138 |
| headache | 1,151 | 1.8 | 1.7 | 420 |
| nausea | 1,012 | 1.3 | 1.2 | 53 |
| off label use | 726 | 0.8 | 0.8 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.